Compare NCRA & AKTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NCRA | AKTX |
|---|---|---|
| Founded | 2002 | N/A |
| Country | Taiwan | United States |
| Employees | N/A | N/A |
| Industry | Farming/Seeds/Milling | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.6M | 6.5M |
| IPO Year | 2022 | 2014 |
| Metric | NCRA | AKTX |
|---|---|---|
| Price | $0.20 | $3.86 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $33.50 |
| AVG Volume (30 Days) | ★ 266.2K | 17.6K |
| Earning Date | 04-15-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $13,627,944.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.17 | $0.12 |
| 52 Week High | $2.40 | $6.59 |
| Indicator | NCRA | AKTX |
|---|---|---|
| Relative Strength Index (RSI) | 37.95 | 41.92 |
| Support Level | $0.18 | $0.36 |
| Resistance Level | $0.24 | $5.50 |
| Average True Range (ATR) | 0.02 | 0.66 |
| MACD | 0.00 | -0.28 |
| Stochastic Oscillator | 15.23 | 2.54 |
Nocera Inc is engaged in the manufacturing of aquaculture equipment, construction of aquaculture facilities, managing and operating aquaculture facilities, and consulting for third-party operators of aquaculture facilities. Its primary business operations consist of the design, development, and production of RASs large-scale fish tank systems, for fish farms along with consulting, technology transfer, and aquaculture project management services to new and existing aquaculture management business services.
Akari Therapeutics PLC is an oncology company developing next-generation antibody-drug conjugates (ADCs) built around novel, proprietary payloads utilizing powerful biology to attack cancer. Its payload, PH1, targets RNA splicing by modulating the spliceosome, a complex machinery in the cell that converts pre-RNA into spliced RNA for translation into vital proteins for cell survival and growth. Its product pipeline is AKTX-101, which targets the Trop2 receptor on cancer cells and, with a proprietary linker, enables it to deliver its novel PH1 payload directly into the tumor with minimal off-target effects. and AKTX-102, an ADC candidate targeting CEACAM5 (Carcinoembryonic Antigen-related Cell Adhesion Molecule-5), a well-validated tumor antigen expressed across multiple solid tumors.